FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
Feature|Articles|December 23, 2025
- December 2025
- Volume 19
- Issue 4
Cancer Care and Education in the Era of Precision Oncology
Author(s)Linda Childers
Fact checked by: Bridget Hoyt, Tracy Ann Politowicz
Oncology nurses and APPs are key players in patient education on precision medicine.
Advertisement
Advertisement
In the era of precision oncology, nurses and advanced practice providers (APPs) do far more than manage chemotherapy or monitor adverse effects (AEs). Today’s cancer care requires a strong understanding of genetics and genomics, as these fields now drive how cancers are detected, treated, and even prevented. Genomic testing is routinely used to identify inherited cancer risks, guide screening strategies, and match patients with targeted therapies.
Related to this article
An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.
FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
FDA approves lutetium lu 177 dotatate (Bravnetsa) as bioequivalent to Lutathera for GEP-NETs. Review key nursing takeaways and safety guidelines.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.
Five-week hypofractionated radiation after prostatectomy showed similar 5-year cancer control and quality of life but more grade 3 urinary toxicity.
Advertisement
Advertisement